Vir Biotechnology (VIR) Earnings Date & Reports

Key Takeaways

• Q2 2026 results are expected after market close on July 30, 2026, with the conference call scheduled for August 5, 2026, at 4:30 p.m. ET.
• Consensus EPS estimate stands at $0.33, a dramatic projected swing from the -$0.85 loss reported in Q1 2026 and the -$0.80 loss in Q2 2025, largely reflecting anticipated revenue recognition from the recently closed Astellas collaboration.
• Revenue estimates are unusually wide, with consensus forecasts ranging from approximately $135.9 million to over $218 million, reflecting uncertainty around the timing and accounting treatment of collaboration-related payments.
• The Astellas collaboration, valued at up to $1.7 billion, closed on April 15, 2026, bringing a $75 million equity investment and a $240 million upfront payment into Q2, significantly strengthening the balance sheet.
• Investors will closely watch updated cash runway guidance and any new clinical data disclosures alongside the financial figures.
• Pipeline catalysts remain abundant, including the ECLIPSE registrational program for chronic hepatitis delta and the Phase 1 expansion of VIR-5500 in prostate cancer.

Earnings Context and Why It Matters

Vir Biotechnology's second-quarter report marks the first full financial period since the company closed its landmark global collaboration with Astellas for VIR-5500, a PSMA-targeted (prostate-specific membrane antigen) T-cell engager for prostate cancer. The quarter also reflects the first reporting period incorporating the proceeds from a $172.5 million follow-on equity offering completed in February. These capital infusions are expected to dramatically reshape the income statement, potentially swinging the company to a quarterly profit after a string of net losses. Beyond the headline numbers, investors will scrutinize pipeline updates — particularly around the chronic hepatitis delta (CHD) program, where Phase 2 SOLSTICE data showed compelling 88% target-not-detected (TND) rates at Week 96, and around the expanding oncology platform.

Earnings Expectations

Wall Street analysts expect Vir Biotechnology to report earnings per share of $0.33 for the second quarter of 2026, according to consensus data compiled by TipRanks and TradingView. This would represent a striking reversal from the -$0.85 per share loss posted in Q1 2026, which itself missed consensus estimates by a wide margin. The anticipated swing to profitability is largely driven by expected revenue recognition tied to the Astellas collaboration, which closed in April and includes a $240 million upfront payment and a $75 million equity investment at $10.36 per share.

Revenue consensus estimates range from approximately $135.9 million (TradingView) to $218.6 million (FX Empire), reflecting considerable uncertainty among analysts about the precise accounting treatment and timing of collaboration proceeds. For context, Vir Biotechnology reported essentially negligible revenue of -$0.03 million in Q1 2026 and only $1.21 million in the prior-year Q2 2025 quarter. The wide dispersion in estimates underscores the complexity of modeling a clinical-stage biotech company amid transformative partnership activity.

Beyond the top and bottom line, investors will focus on updated cash guidance. The company ended Q1 2026 with $809.3 million in cash, cash equivalents, and investments, excluding the $315 million in Astellas-related proceeds that landed in Q2. Management previously guided that its cash runway extends into the second half of 2028, and any revision to that timeline would be closely scrutinized. Research and development (R&D) expenses — which ran at $108.9 million in Q1 — along with selling, general and administrative (SG&A) expenses will also be important metrics to monitor for evidence of disciplined capital allocation.

AI Screener

For investors seeking to identify opportunities across the biotechnology sector and beyond, Tickeron's AI Screener offers an AI-powered stock and ETF discovery platform designed to streamline the research process. The tool allows traders and investors to filter thousands of securities using customizable criteria such as industry classification, market capitalization, technical indicators, price patterns, volatility metrics, and AI-driven trading signals. By surfacing stocks that match specific technical or fundamental profiles, the AI Screener helps users spot breakout candidates, trending names, and trade ideas far more efficiently than manual screening methods permit. For those tracking earnings season movements across the healthcare and biopharma landscape, the screener can serve as a practical starting point for deeper analysis.

Market Reaction and Investor Sentiment

Heading into the Q2 earnings release, investor sentiment around Vir Biotechnology has been cautiously optimistic, supported by the momentum of the Astellas collaboration and encouraging clinical data across the pipeline. The stock has benefited from increased visibility following the February follow-on offering and the April deal closing. However, the memory of the Q1 2026 earnings miss — where EPS of -$0.85 came in far below the -$0.01 consensus — remains fresh, and investors are likely to approach this report with a degree of skepticism about whether deal-related revenue will translate into a clean bottom-line beat.

Key risk factors heading into the print include the unpredictability of collaboration revenue recognition, the trajectory of R&D spending as the ECLIPSE registrational studies and oncology programs advance, and broader market sentiment toward pre-revenue biotech names. A meaningful miss on either the revenue or EPS line — particularly if collaboration-related payments are not recognized as expected — could trigger a volatile post-earnings reaction. Conversely, a solid beat paired with constructive pipeline updates and reaffirmed cash runway could reinforce the narrative that Vir Biotechnology is entering a new phase of value creation.

Forward Outlook and Key Factors to Monitor

Looking beyond the Q2 2026 print, several critical milestones will shape Vir Biotechnology's investment narrative over the coming quarters.

The CHD registrational program remains the company's most advanced value driver. The ECLIPSE 1 trial, which is evaluating the combination of tobevibart and elebsiran, is on track to deliver topline data in the fourth quarter of 2026. That readout — if positive — could position Vir Biotechnology to file for regulatory approval in a therapeutic area with significant unmet need, where only 10% to 15% of the estimated 61,000 actively viremic U.S. patients are currently diagnosed.

In oncology, the VIR-5500 program with partner Astellas is advancing through Phase 1 dose-expansion cohorts, with plans to initiate a registrational Phase 3 study in 2027. Early data has been encouraging, with no dose-limiting toxicities and no Grade 3 cytokine release syndrome (CRS) observed at the highest dose levels tested. Additionally, the broader PRO-XTEN dual-masked T-cell engager platform — including VIR-5818 and VIR-5525 — is generating incremental data updates, with preliminary monotherapy and pembrolizumab combination results expected later in 2026.

On the financial side, investors should track the pace of cash consumption. The Astellas deal reduces near-term development spending through a 40/60 cost-sharing arrangement, but the company's aggregate R&D and SG&A expenses remain substantial. Clarity on the ongoing cash burn rate and any adjustments to the "into the second half of 2028" runway guidance will be essential for assessing how much financial flexibility the company has to reach key clinical inflection points without additional capital raises.

Disclaimer

The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.

Disclaimers and Limitations